Indobufen
Authors:
- 1 January 2001
- journal article
- research article
- Published by Springer Nature in Drugs & Aging
- Vol. 18 (5) , 369-388
Abstract
Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclo-oxygenase enzyme thereby suppressing thromboxane synthesis. Clinical trials have evaluated the efficacy of oral indobufen in the secondary prevention of thromboembolic complications in patients with or without atrial fibrillation, in the prevention of graft occlusion after coronary artery bypass graft (CABG) surgery and in the treatment of intermittent claudication. In the secondary prevention of thromboembolic events indobufen 200mg once or twice daily was significantly more effective than no treatment although not as effective as ticlopidine 250mg once or twice daily, during 1-year nonblind clinical trials. Compared with placebo, indobufen 100mg twice daily significantly reduced the risk of stroke in a small 28-month trial of patients at increased risk of systemic embolism (50% had atrial fibrillation). Furthermore, in patients with nonrheumatic atrial fibrillation and a recent cerebrovascular event enrolled in the 1-year Studio Italiano Fibrillazione Atriale (SIFA) trial, indobufen 100 or 200mg twice daily was as effective as warfarin (titrated to produce an international normalised ratio of 2.0 to 3.5) in the secondary prevention of thromboembolic events; the incidences of the composite end-point of major vascular events (10.6 vs 9.0%) and recurrent stroke (5 vs 4%) were similar between treatments. In 2 large 12-month trials, the Studio Indobufene nel Bypass Aortocoronarico (SINBA) and the UK study, indobufen 200mg twice daily was as effective as aspirin (acetylsalicylic acid) 300 or 325mg plus dipyridamole 75mg 3 times daily in the prevention of early and late occlusion of saphenous grafts in patients after CABG surgery. Indobufen 200mg twice daily for 6 months significantly improved walking capacity compared with placebo, and caused a more pronounced improvement in both pain-free and total walking distance than either pentoxifylline 300mg or aspirin 500mg twice daily in separate 6- and 12-month studies of patients with intermittent claudication. Oral indobufen up to 200mg twice daily was generally well tolerated in >5000 patients with atherosclerotic disease. Adverse events (predominantly gastrointestinal), reported by 3.9% of patients, rarely required withdrawal from treatment. In the SINBA and UK studies, fewer adverse events and less gastrointestinal bleeding were seen with indobufen than with aspirin plus dipyridamole treatment, while in the SIFA trial, noncerebral bleeding events occurred significantly less frequently in indobufen than warfarin recipients (0.6 vs 5.1%) and major bleeding events occurred only in the warfarin group. Conclusion: Indobufen is as effective as warfarin in the prophylaxis of thromboembolic events in at risk patients with nonrheumatic atrial fibrillation, as aspirin plus dipyridamole in the prevention of CABG occlusion and may be more effective than aspirin or pentoxifylline in improving walking capacity in patients with intermittent claudication. The improved tolerability profile of indobufen (favourable gastric tolerance and reduced haemorrhagic complications) compared with aspirin 300 to 325mg 3 times daily or warfarin, in addition to a similar antiplatelet effect, suggests indobufen can be considered a drug with a definite role in the management of atherothrombotic events. In particular, indobufen may be an effective alternative for at risk patients with nonrheumatic atrial fibrillation in whom anticoagulant therapy is contraindicated or who are at higher risk of bleeding. Indobufen, an isoindolinyl phenyl-butyric acid derivative, reversibly inhibits platelet aggregation in vitro and ex vivo at the level of platelet cyclo-oxygenase, thereby suppressing thromboxane A2 production (a potent platelet activator). Ex vivo suppression of platelet thromboxane synthesis is evident within 2 hours of indobufen administration (98%), is still significant at 12 hours (89%) yet attenuated at 24 hours (47%), indicating reversible inhibition. Indobufen inhibits the release reaction and the secondary wave of aggregation induced by the platelet agonists adenosine diphosphate, adrenaline (epinephrine) and platelet activating factor in platelets taken from healthy volunteers and patients with ischaemic heart disease, atherosclerosis or angina pectoris. The maximum inhibitory effect on agonist-induced platelet aggregation was observed 2 hours after a single oral dose of indobufen 200mg and this inhibition was reversible, with platelet aggregation returning to baseline values within 24 hours. Indobufen alone or in combination with pentoxifylline reduces levels of β-thromboglobulin and platelet factor 4, markers of platelet activation. Other effects of indobufen include decreased platelet adhesiveness and an improvement in red blood cell deformability. Bleeding time is prolonged following indobufen administration, although within the upper limit of normal and for a shorter time than with aspirin (acetylsalicylic acid) or ticlopidine. Improvements in microcirculatory parameters including skin blood flow and the venoarteriolar reflex were shown in patients with intermittent claudication following indobufen therapy. Indobufen inhibited thrombus formation in animals and prevented graft occlusion following vascular surgery. Indobufen is rapidly and completely absorbed after oral administration, reaching peak plasma concentrations within 2 hours. The elimination half-life (t1/2β) is about 7 hours and the low apparent volume of distribution of 15L is a reflection of the high plasma protein binding (>99%) of the drug. The fraction of the administered dose excreted in urine within 48 hours of administration is about 70 to 80%, with most excreted via the kidney as glucuronic acid conjugates and 11 to 13% excreted as unchanged drug. Excretion rates are not affected by route of administration (oral or intravenous) and renal clearance is not affected by the presence of food. Dose reductions may be required in the elderly and patients with renal insufficiency, because the clearance of indobufen is significantly prolonged in these populations. Few drug interactions have been reported with indobufen, although an increase in the area under the concentration-time curve (AUC) of glipizide has been documented. Secondary Prevention of Thromboembolic Events in At Risk Patients. Indobufen 200 mg/day was significantly more effective than no treatment in the secondary prevention of thromboembolic events (9.5 vs 28.6%, p < 0.025) in a small (n = 84) randomised 1-year study of patients with a previous vertebrobasilar transient ischaemic attack. In the nonblind, multicentre, Ticlopidine Indobufen Stroke Study (TISS), indobufen 200mg was not as effective as ticlopidine 250mg, both once or twice daily for up to 1 year in the prophylaxis of thromboembolic events in 1632 patients with a recent minor stroke, transient ischaemic attack or an amaurosis fugax. The incidence of any cerebrovascular event or death was significantly lower in the ticlopidine than in the indobufen group (2.9 vs 5.8%). In Patients with Nonrheumatic Atrial Fibrillation. A significant reduction (3-fold) in the risk of stroke was seen with indobufen 100mg twice daily compared with placebo in a double-blind, 28-month trial of 196 patients with heart disease at increased risk of cardiogenic embolism (50% had atrial fibrillation). The incidence of the composite end-point of cerebral ischaemic attacks, systemic or pulmonary embolism and fatal myocardial infarction (MI) was significantly lower with indobufen treatment than with placebo (6 vs 17%, p < 0.05). Furthermore, in the Studio Italiano Fibrillazione Atriale (SIFA) trial, indobufen 100 or 200mg twice daily was as effective as warfarin (titrated to achieve an international normalised ratio of 2.0 to 3.5) in the secondary prevention of thromboembolic events in 916 patients with nonrheumatic atrial fibrillation and a recent (≤15 days) cerebral ischaemic event. There was no significant difference in the incidence of the composite end-point of nonfatal stroke or MI, systemic or pulmonary embolism and vascular death (10.6 vs 9.0%) during the 12-month study, or in the incidence of recurrent stroke (5 vs 4%) at follow-up. Maintenance of Graft Patency. In large, well controlled 12-month trials the Studio Indobufene nel Bypass Aortocoronarico [SINBA] (n = 569) and the UK study (n = 803) indobufen 200mg twice daily was as effective as a standard regimen of aspirin 300 or 325mg plus dipyridamole 75mg 3 times daily in preventing early and late occlusion of coronary artery bypass grafts. Indobufen 200mg twice daily was also as effective as aspirin 300mg plus dipyridamole 75mg 3 times daily in the prevention of early or late femoropopliteal polytetrafluoroethylene graft occlusion over a 1-year study period, although results in other trials have been conflicting. Intermittent Claudication. In randomised trials of patients with intermittent claudication, indobufen 200mg twice daily for 6 months significantly improved pain-free walking distance (in 2 trials) and total walking distance (in 1 trial) compared with placebo (p < 0.01). In 2 comparative studies, indobufen 200mg twice daily for 6 or 12 months caused a more pronounced improvement in both pain-free and total walking distance than either pentoxifylline 300mg or aspirin 500mg twice daily (which worsened these parameters). In a postmarketing surveillance study of >5000 patients with atherosclerotic disease, indobufen 200mg twice daily for ≥2 months was generally well tolerated. Adverse events occurred in 3.9% of patients and were predominantly gastrointestinal (78% of events) along with disorders of haemostasis and coagulation (7.8%), skin (7.1%) and CNS disturbances (4.1%). In the SINBAand UK studies, significantly fewer adverse events and instances of gastrointestinal bleeding were seen with indobufen 400 mg/day than with aspirin ≥900 mg/day plus dipyridamole 225 mg/day, 9 vs 18% and 38 vs 45%, respectively. Similarly, reports of adverse events in the SIFA trial were less frequent in the indobufen than in the warfarin group (21 mainly gastrointestinal vs 33 mainly bleeding events) and the incidence of noncerebral bleeding events was significantly lower (0.6 vs 5.1%, p < 0.01) while major bleeding events occurred only in the warfarin group (0.9%). Indobufen is indicated in Italy for the prophylaxis of thromboembolic complications in patients with ischaemic cerebrovascular and heart diseases, peripheral vascular disease of an atherosclerotic nature, venous thrombosis, lipid metabolism disorders and diabetes mellitus, and during extracorporeal circulation (haemodialysis). The recommended oral dosage of indobufen is 200 to 400 mg/day in 2 divided doses. Dosage reductions to 100 to 200 mg/day are warranted in the elderly and patients with renal impairment according to their degree of renal insufficiency. Indobufen is also available in a parenteral form for either intravenous or intramuscular administration (same dosages as the oral formulation).Keywords
This publication has 66 references indexed in Scilit:
- Thrombotic Thrombocytopenic Purpura Associated with ClopidogrelNew England Journal of Medicine, 2000
- Pharmacological Management of Intermittent ClaudicationDrugs, 2000
- Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial FibrillationStroke, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- IndobufenDrugs, 1992
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk PatientsNew England Journal of Medicine, 1989
- THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKEThe Lancet, 1989
- In vitro and ex vivo Effects of Indobufen on Human Platelet Aggregation, the Release Reaction and Thromboxane B2 ProductionPathophysiology of Haemostasis and Thrombosis, 1987
- Clinical Pharmacology Studies with Indobufen (K 3920): Inhibitor of Platelet AggregationThe Journal of Clinical Pharmacology, 1980